Display options
Cite
Akin Y, Gulmez H, Ates M, et al. Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial. Iran Red Crescent Med J. 2013;15(10):e13805doi: 10.5812/ircmj.13805.
Akin, Y., Gulmez, H., Ates, M., Bozkurt, A., & Nuhoglu, B. (2013). Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial. Iranian Red Crescent medical journal, 15(10), e13805. https://doi.org/10.5812/ircmj.13805
Akin, Yigit, et al. "Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial." Iranian Red Crescent medical journal vol. 15,10 (2013): e13805. doi: https://doi.org/10.5812/ircmj.13805
Akin Y, Gulmez H, Ates M, Bozkurt A, Nuhoglu B. Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial. Iran Red Crescent Med J. 2013 Oct;15(10):e13805. doi: 10.5812/ircmj.13805. Epub 2013 Oct 05. PMID: 24693363; PMCID: PMC3950775.
Copy Download .nbib Format: NLM
Share it on

Iran Red Crescent Med J. 2013 Oct;15(10):e13805. doi: 10.5812/ircmj.13805. Epub 2013 Oct 05.

Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial.

Iranian Red Crescent medical journal

Yigit Akin, Hakan Gulmez, Mutlu Ates, Aliseydi Bozkurt, Baris Nuhoglu

Affiliations

  1. Harran University School of Medicine, Department of Urology, Sanliurfa, Turkey.
  2. Department of Family Medicine, Baskent University School of Medicine, Ankara, Turkey.
  3. Department of Urology, Afyon Kocatepe University School of Medicine, Afyonkarahisar, Turkey.

PMID: 24693363 PMCID: PMC3950775 DOI: 10.5812/ircmj.13805

Abstract

BACKGROUND: Premature ejaculation (PE) is the most common sexual disorder in men and studies reported prevalence up to 30% (1, 2). PE is not a life-threatening medical condition but it influences the quality of life (QoL).

OBJECTIVES: The aim of this study was to compare the efficiency, and safety of alpha blocker drugs in the treatment of patients with premature ejaculation (PE). Additionally we investigated the quality of life (QoL) in patients with PE who were treated with alpha blocker drugs.

MATERIALS AND METHODS: This study was a pilot clinical trial. Prospectively documented 108 patients with PE were treated and were followed-up in urology outpatient clinic. All patients were divided into 5 groups according to used alpha blocker agents which were determined by simple randomization. Silodosin 4mg (Group 1, n = 21), tamsulosin hydrochloride 0.4mg (Group 2, n = 23), alfuzosin 10mg (Group 3, n = 22), terazosin 5mg (Group 4, n = 21), doksazosin mesylate 4mg (Group5, n = 21), were used for treatment. The demographic parameters of patients, pre and post treatment intravaginal ejaculation latency time (IELT), PE Profile (PEP), and QoL index were recorded and evaluated. Effectiveness of treatment was evaluated by measuring IELT. Additionally, side effects of drugs were recorded. P < 0.05 was considered statistically significant.

RESULTS: All alpha blocker drugs were statistically effective for preventing PE. Notably, silodosin seemed to be more effective for preventing PE than other alpha blockers (P < 0.05). However all alpha blockers provided development in QoL scores, silodosin was a little better than other drugs in statistical analyses. Furthermore statistical increase in IELT and decrease in PEP were provided more in Group 1 than other groups (P < 0.05).

CONCLUSIONS: Silodosin seems to be able to even more prevent PE. Silodosin may provide development in QoL than other alpha blocker agents. Additionally, lower systemic adverse events and more effectivity are the prominent features of silodosin in PE.This study was a pilot clinical trial. Prospectively documented 108 patients with PE were treated and were followed-up in urology outpatient clinic. All patients were divided into 5 groups according to used alpha blocker agents which were determined by simple randomization. Silodosin 4mg (Group 1, n = 21), tamsulosin hydrochloride 0.4mg (Group 2, n = 23), alfuzosin 10mg (Group 3, n = 22), terazosin 5mg (Group 4, n = 21), doksazosin mesylate 4mg (Group5, n = 21), were used for treatment. The demographic parameters of patients, pre and post treatment intravaginal ejaculation latency time (IELT), PE Profile (PEP), and QoL index were recorded and evaluated. Effectiveness of treatment was evaluated by measuring IELT. Additionally, side effects of drugs were recorded. P < 0.05 was considered statistically significant.

Keywords: Premature Ejaculation; Quality of Life; Serotonin Uptake Inhibitors

References

  1. Int J Urol. 2012 Mar;19(3):268-72 - PubMed
  2. J Fam Pract. 2001 Sep;50(9):773-8 - PubMed
  3. Eur Urol. 2010 May;57(5):804-14 - PubMed
  4. Eur Urol. 1995;28(2):126-30 - PubMed
  5. J Urol. 1996 Nov;156(5):1631-2 - PubMed
  6. J Urol. 2004 Jul;172(1):290-4 - PubMed
  7. Lancet. 2006 Sep 9;368(9539):929-37 - PubMed
  8. BJU Int. 2006 Nov;98(5):1019-24 - PubMed
  9. J Sex Marital Ther. 1997 Spring;23(1):3-23 - PubMed
  10. Eur Urol. 2006 Sep;50(3):454-66 - PubMed
  11. J Sex Med. 2008 Jun;5(6):1296-307 - PubMed
  12. Rev Urol. 2009 Fall;11(Suppl 1):S1-8 - PubMed
  13. Int Urol Nephrol. 2005;37(4):773-7 - PubMed
  14. Urol Clin North Am. 2001 May;28(2):363-75, x - PubMed
  15. J Urol. 1996 Nov;156(5):1783-4 - PubMed
  16. J Sex Med. 2012 Jan;9(1):159-68 - PubMed
  17. Andrologia. 2002 Dec;34(6):356-9 - PubMed
  18. J Urol. 2001 Dec;166(6):2325 - PubMed
  19. Adv Ther. 2002 Jan-Feb;19(1):17-26 - PubMed
  20. J Sex Med. 2011 Feb;8(2):540-8 - PubMed
  21. J Sex Med. 2008 Sep;5(9):2185-90 - PubMed

Publication Types